ISO 9001:2008 certified   For more information | Call (262) 293-0251

FAQ

Frequently Asked Questions on Rapid Precursor Development™

Please click on the question to see the answer. In addition, please feel free to contact us for more details.

1. What is Rapid Precursor Development™?

There is a huge gap between benchtop lab work and full commercial production. The difficult, production development cycle can be 5 to 10 years. RPD breaks that down. 

What if benchtop to commercial production could be cut by as much as half? That is significant. 

But, many large companies simply cannot move like this. Their political or other type of system does not allow for it. Nova-Kem is defining a new methodology and a new industry - one that moves like lightning rather than at a turtle's pace. In technology and other specialty chemically-based spaces, speed can make the difference between conquering or being another one in the crowd.

RPD is the methodology for accelerating the time it takes to go from small scale R&D synthesis of a precursor to the time it takes to reach full scale commercial production.

 


Comment

No Very




Captcha Image

2. Where did the term ‘Rapid Precursor Development™’ come from?

As with most large companies in industry, more resources usually mean more paperwork and bureaucracy, which take a heavy toll on speed and efficiency. This issue becomes more acute in the world of chemistry where benchtop synthesis and commercial production are two very separate activities that carry their own challenges and requirements. The fact is that the scale-up process that takes place between bench top synthesis and commercial production is all too often treated as an afterthought, when in fact it demands equal time. Virtually every company that has undertaken this type of work has experienced success on “bench” which did not equate to success on scale-up and production.

In the process of developing Hexachlorodisilane (HCDS), Nova-Kem became acutely aware of our ability to bring this highly sought after precursor from the bench lab to full-scale production in a fraction of the time taken by bigger companies that have resources well beyond those of Nova-Kem.  

Our success in this area can be attributed to:

  1. Our ability to avoid the large company trap of ‘paralysis by analysis’, slow to make decisions and even slower to act on them
  2. Our ability to recognize the scale up process as an extension of research and development
  3. Commitment to be willing to make the necessary investment and allocation of resources that it would take to complete the scale up.

Comment

No Very




Captcha Image

3. What companies would benefit from engaging in ‘Rapid Precursor Development™’?

The simple fact is that proof of concept in the lab does not meet production needs. Commercial production does, and the faster that you can get to this point, the faster you can start to improve production capabilities. 

There are 3 general company profiles that would greatly benefit from RPD™:

  1. Small companies with limited R&D capabilities that have a specific use, either internally or for their clients, for a specific precursor.
  2. Small companies that have sufficient R&D capabilities but lack the resources to engage in the scale-up phase.
  3. Large companies that have the resources to address both benchtop R&D and full-scale production, but may be limited by time or lacking specialized equipment for certain R&D or scale-up phase.

Comment

No Very




Captcha Image

4. What makes Nova-Kem an authority on ‘Rapid Precursor Development™’?

Being the first of its kind certainly adds a level of credibility, but this is more form over substance. 

The substance comes from the fact that Nova-Kem is accomplished in the RPD™ process. We have proven it in areas like HCDS and in so doing have determined that the process is unique enough to warrant its own label. Furthermore, Nova-Kem’s RPD™ initiative is under the direction of Dr. Marek Boleslawski, a precursor scientist of global acclaim, who brings over four decades of precursor development experience and Mr. Reno Novak who pioneered the commercial development of HCDS.

It was Reno Novak who first pioneered the Rapid Precursor Development™ phrase and developed its methodologies and standards.


Comment

No Very




Captcha Image

5. What type of relationship can we establish with Nova-Kem with regard to a desired ‘Rapid Precursor Development™’ project?

We enjoy an entrepreneurial spirit, and we love working with others who share the same heartbeat. Nova-Kem is open to any relationship that helps to develop and expand the industry or has production/expertise needs. 

For the most part, we enjoy relationships falling under one of the following scenarios;

  1. Traditional client/vendor relationship where the client contracts Nova-Kem to produce a precursor for a fee. The client would own any intellectual property (IP) associated with the precursor and could choose to use Nova-Kem or any other vendor for commercial production.
  2. A business collaboration where the client identifies a specific precursor, pays a nominal fee for some level of discovery, and Nova-Kem shares in the IP and future success of the precursor.
  3. A full collaboration at the R&D level where the client/vendor relationship becomes more of a true partnership with both parties sharing in the risk / reward of the project.

Comment

No Very




Captcha Image

Rapid Precursor Development™